Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients

Abstract In vitro, Imatinib inhibits the proliferation and stimulates the osteogenic and adipogenic differentiation of mesenchymal stromal cells (MSC). However, it is unknown whether Imatinib affects the biology of MSC in vivo. We asked whether MSC from long-term Imatinib-treated CML patients were a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2014-05, Vol.38 (5), p.594-600
Hauptverfasser:	Estrada-González, P.K, Gómez-Ceja, L, Montesinos, J.J, Mayani, H, Chávez-González, A, Meillón, L, Delgado, N, Sánchez-Nava, E, Flores-Figueroa, E
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Benzamides - therapeutic use Bone remodeling Cell Differentiation Chronic myeloid leukemia Fibrosis Fusion Proteins, bcr-abl - metabolism Hematology, Oncology and Palliative Medicine Humans Imatinib Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Mesenchymal stromal cells Mesenchymal Stromal Cells - cytology Mesenchymal Stromal Cells - physiology Phenotype Piperazines - therapeutic use Pyrimidines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!